ASCO 2022 Conference Coverage


 

Health-Related Quality of Life in R/R MM Treated With Teclistamab, a B-Cell Maturation Antigen x CD3-Bispecific Antibody: PROs in MajesTEC-1

773 views
June 20, 2022
This video was recorded prior to the FDA approval of teclistamab-cqyv (TECVAYLI) for adult patients ...
read more ↘
Comments 0
Login to view comments. Click here to Login